Related Experiment Video
Updated: Aug 16, 2025
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
Claudio Martin1,2, Diego Enrico1,2
1Department of Medical Oncology, Thoracic Oncology Section, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.
Abstract:
During the past decade, immunotherapy has dramatically improved the outcomes of patients with non-small cell lung cancer (NSCLC). The development of specific antibodies against the programmed death (PD1) receptor and its ligand PD-L1 (programmed death ligand-1) has demonstrated substantial efficacy in advanced NSCLC either in the first or in the second line. However, the success of immune checkpoint inhibitors (ICIs) as monotherapy did not reach all patients and long-term responders still represent a small subset of cases. Under these circumstances, different strategies have been and are being tested to optimize clinical outcomes. Here, we reviewed the current evidence and the more promising perspectives of ICI combination approaches, such as the addition of chemotherapy, antiangiogenic agents, other co-inhibitory or co-stimulatory checkpoints, and targeted therapies.
Insights
Immunotherapy, including immune checkpoint inhibitors (ICIs), has advanced non-small cell lung cancer (NSCLC) treatment. Combinations with chemotherapy, antiangiogenic agents, and targeted therapies aim to improve outcomes for more patients.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Immunotherapy, specifically immune checkpoint inhibitors (ICIs) targeting PD1/PD-L1, has significantly improved outcomes in advanced non-small cell lung cancer (NSCLC).
- Despite successes, monotherapy with ICIs benefits only a subset of patients, highlighting the need for improved treatment strategies.
Purpose of the Study:
- To review current evidence on combination approaches involving ICIs in NSCLC treatment.
- To explore promising future perspectives for optimizing clinical outcomes with ICI combinations.
Main Methods:
- Literature review of clinical studies and research on ICI combination therapies for NSCLC.
- Analysis of data regarding the efficacy and safety of various combination strategies.
Main Results:
- ICIs targeting PD1/PD-L1 show efficacy in advanced NSCLC, but long-term responses are limited in some patients.
- Combination strategies, including chemotherapy, antiangiogenic agents, other immune checkpoints, and targeted therapies, are under investigation to enhance treatment effectiveness.
Conclusions:
- Combination therapies hold significant promise for improving response rates and long-term survival in NSCLC patients treated with ICIs.
- Further research into optimized ICI combinations is crucial for maximizing clinical benefits in non-small cell lung cancer.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...